“Halol clearance is a positive development for Sun, as approvals from the facility have been delayed for the past three years. The company has 139 pending abbreviated new drug application (ANDA), of which the Halol site is a key contributor in terms of pending ANDA and some may be of limited competition in nature,” said analysts Elara Capital in a note. They believe the stock factors in most positives at the current levels and maintain a ‘reduce’ rating with a price target of Rs 482.
Reliance Securities, on the other hand, expects Aurobindo Pharma’s US business to clock 11 per cent compounded annual growth (CAGR) over FY18-20, led by new launches (30-40 in FY19 including few niche products) and a ramp-up in injectable business. The brokerage recommends buying the stock with a price target of Rs 712.
Dr Reddy’s Laboratories, Lupin, Cadila Healthcare, Wockhardt, Aurobindo Pharma
and Glenmark Pharmaceuticals from the frontline pharma
pack have gained 12 per cent to 17 per cent in past six sessions.
Going ahead, Chokkalingam expects the rally to continue and sees an upside of 10 per cent – 15 per cent from here on, but suggests investors remain selective and look at the company’s future growth potential before investing. Of the lot, he likes Lupin
at the current levels.
Despite 12 per cent rally in past six trading sessions, the Nifty Pharma
index has underperformed the market by falling 5.6 per cent thus far in the calendar year 2018 (CY18). In comparison, the benchmark index has gained up 3.2 per cent since then.
Bhavesh Gandhi, an analyst tracking the sector at IIFL remains cautious on the sector and suggests that the rebound in the stocks may not last long. The US market, he believes, still remains a key pivot for Indian pharma
“We remain cognizant of the fall in frontline stocks, but the rebound, as and when it happens, would not lift all boats. Retain underweight stance with a liking for select stocks like IPCA Labs and Laurus Labs,” he says.